A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients
This study has been completed.
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
First received: November 2, 1999
Last updated: July 26, 2013
Last verified: July 2013
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||September 1999|
|Estimated Primary Completion Date:||No date given|
Demeter LM, Degruttola V, Lustgarten S, Bettendorf D, Fischl M, Eshleman S, Spreen W, Nguyen BY, Koval CE, Eron JJ, Hammer S, Squires K. Association of Efavirenz Hypersusceptibility with Virologic Response in ACTG 368, a Randomized Trial of Abacavir (ABC) in Combination with Efavirenz (EFV) and Indinavir (IDV) in HIV-Infected Subjects with Prior Nucleoside Analog Experience. HIV Clin Trials. 2008 Jan-Feb;9(1):11-25.